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The mitogen-activated protein kinase (MAPK) pathway plays a central role
in colorectal cancers (CRC). In particular, BRAF V600E-mutant tumors,
which represent around 10% of CRCs, are refractory to current therapies.
Overexpression and secretion of serine peptidase inhibitor Kazal type 1
(SPINK1) are observed in around 50% of CRCs, and its serum level can
be used as a biomarker for poor prognosis. Utilizing a recently developed
extendable blocking probe assay, we analyzed the BRAF mutation status
in a CRC patient cohort (N = 571) using tissue-derived RNA as the start-
ing material. From the same RNA samples, we measured the relative
SPINK1 expression levels using a quantitative real-time PCR method.
Expression of mutant BRAF V600E correlated with poor prognosis, as did
low expression of SPINK1 mRNA. Further, BRAF V600E correlated neg-
atively with SPINK1 levels. In order to investigate the effect of MAPK
pathway-targeted therapies on SPINK1 secretion, we conducted in vitro
studies using both wild-type and V600E CRC cell lines. BRAF inhibitor
vemurafenib, and subsequent MAPK pathway inhibitors trametinib and
SCH772984, significantly increased SPINK1 secretion in V600E CRC cell
lines Colo205 and HT-29 with a concomitant decrease in trypsin-1 and -2
secretion. Notably, no SPINK1 increase or trypsin-1 decrease was observed
in BRAF wild-type CRC cell line Caco-2 in response to MAPK pathway
inhibitors. In further mechanistic studies, we observed that only trametinib
was able to diminish completely both MEK and ERK phosphorylation in
the V600E CRC cells. Furthermore, the key regulator of integrated stress
response, activating transcription factor 4 (ATF-4), was downregulated
both at mRNA and at protein level in response to trametinib treatment. In
conclusion, these data suggest that sustained inhibition of not only MAPK
pathway activation, but also ATF-4 and trypsin, might be beneficial in the
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therapy of BRAF V600E-mutant CRC and that SPINK1 levels may serve
as an indicator of therapy response.
1. Introduction
Colorectal cancer (CRC) is the third most common
cancer in men and the second in women worldwide.
While about 20% of patients have disseminated disease
at diagnosis, part of the patients initially classified as
having regional disease and even some of those with
local disease will develop a recurrence and eventually
die from cancer. Overall 5-year survival is 50–60% (Sie-
gel et al., 2012). Current FDA-approved molecularly
targeted therapies for metastasized CRC include several
monoclonal antibodies against vascular endothelial
growth factor and epidermal growth factor receptor
(EGFR), a multikinase small-molecule inhibitor rego-
rafenib, and a nucleoside analog trifluridine/tipiracil
(Moriarity et al., 2016). Currently available EGFR
antibodies cetuximab and panitumumab bind to the
extracellular domain of EGFR resulting in receptor
internalization and blockage of signaling. Mutations in
the RAS family of proto-oncogenes (KRAS, NRAS,
HRAS) result in constitutive activation of the mitogen-
activated protein kinase (MAPK) pathway signaling
independent of activation of receptor tyrosine kinases
such as EGFR. Therefore, mutations in KRAS or
NRAS cause intrinsic resistance to EGFR-targeted
therapies (Semrad and Kim, 2016).
V600E mutation in BRAF, which is immediately
downstream of RAS, has also been proposed to cause
resistance to anti-EGFR antibodies. This mutation is
found in about 10% of CRCs leading to an aggressive
subtype, for which there is no effective oncological ther-
apy (Dienstmann and Tabernero, 2016). Unexpectedly,
specific BRAF V600E inhibitors, such as vemurafenib
that is highly effective in melanoma, do not benefit
patients with CRC. Subsequently, it was shown that
intrinsic resistance to vemurafenib in CRC is caused by
EGFR autoactivation through an unknown mechanism
(Prahallad et al., 2012). In recent clinical trials, a combi-
nation of a BRAF V600E inhibitor with a MEK (Cor-
coran et al., 2015) or a PI3K (Elez et al., 2015) inhibitor
showed a clinical benefit. Therefore, sustained MAPK
inhibition appears to be a critical determinant of the
clinical benefit, and differing from melanoma, it seems
that only combinations are able to generate therapeutic
effects in CRC (Dienstmann and Tabernero, 2016).
Overexpression and secretion of serine peptidase
inhibitor Kazal type 1 (SPINK1, also known as
tumor-associated trypsin inhibitor, or pancreatic secre-
tory trypsin inhibitor) are observed in a variety of can-
cers (R€as€anen et al., 2016a). In CRC, increased
SPINK1 serum levels are found in around 50% of
patients, and it is an independent prognostic factor
(Gaber et al., 2010). However, the prognostic value of
tissue expression of SPINK1 in CRC is controversial,
as depending on study it has been predictive of either
poor or good prognosis, or nonsignificant (Chen et al.,
2015; Koskensalo et al., 2013 (Ida et al., 2015). We
have previously shown that concomitant SPINK1 and
EGFR expression in CRC tissue predicts favorable
prognosis (Koskensalo et al., 2013); Koskensalo et al.
(2012) and Chen et al. (2016) showed that high tissue
expression of SPINK1 in CRC correlated with a better
prognosis.
In addition to intrinsic resistance, acquired resis-
tance presents a clinical problem as a majority of the
patients who are treated with molecularly targeted
treatments relapse within a year. Therefore, both novel
methods and novel biomarkers that predict treatment
response are needed for the stratification of patients in
order to select appropriate therapy. In the current
study, we investigated the expression of BRAF V600E
mutations in a CRC cohort of 571 patients using a
novel extendable blocking probe reverse transcriptase
(ExBP-RT) assay that we recently developed. ExBP-
RT is an ultra-high selective method and allows for
analysis of expressed mutations at the RNA level (Ho
et al., 2015). This method therefore enables analysis of
mutational status irrespective of whether the mutation
is inherited or acquired. The use of tumor tissue RNA
instead of DNA as the starting material enabled us to
correlate the mRNA expression of BRAF V600E
mutations directly with SPINK1 mRNA expression
level analyzed by qPCR from the same tumor samples.
Further, using BRAF wild-type and V600E CRC cell
lines, we studied the effects of MAPK inhibitors on
SPINK1 secretion in vitro.
2. Materials and methods
2.1. RNA samples
RNA was extracted as described (Ho et al., 2015)
from formalin-fixed, paraffin-embedded (FFPE)
samples from patients who were operated for
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histologically confirmed CRC at the Department of
Surgery, Meilahti Hospital, Helsinki University Hospi-
tal between 1987 and 2003. In total, 571 patients’ sam-
ples were available for this study. The use of clinical
samples for this purpose was approved by the Surgical
Ethics Committee of Helsinki University Hospital and
the National Supervisory Authority of Welfare and
Health and collected from the archives of the Depart-
ment of Pathology, Helsinki University Hospital. All
RNA samples were quantified with a NanoVue spec-
trophotometer (GE Healthcare, Waukesha, WI, USA).
Table 1 describes the clinicopathological features of
the cohort.
2.2. ExBP-RT assay
The extendable blocking probe method (Ho et al.,
2015) was employed for ultrasensitive detection of the
BRAF V600E gene mutation. Using RNA templates,
this novel method allows for the detection of expressed
mutations in at least a 1000 times higher background
of the corresponding wild-type alleles. The principles
of ExBP-RT assays and reaction setup procedures for
multiplex detection of BRAF V600E mutation were as
described in the original paper (Ho et al., 2015).
RNA extracted from FFPE samples was diluted to
100 nglL1 in DEPC H2O for the ExBP-RT assay,
before the allele-specific reverse transcription reaction.
RNA extracted from Colo205 (BRAF V600E mutant)
and A549 (BRAF wild-type) cell lines were used as
positive and negative controls, respectively, in ExBP-
RT assays of BRAF mutation detection. All control
RNAs were extracted from cultured cells using RNA/
DNA purification Kit (Norgen Biotek, Thorold, ON,
Canada), quantified with a NanoVue spectrophotome-
ter (GE Healthcare), and diluted to 100 nglL1 in
DEPC H2O.
Using cDNA products of the ExBP-RT assays as a
template, the real-time PCR amplification was per-
formed to detect/quantify the expression of mutant
BRAF V600E. QuantiTect Probe PCR Kits (Qiagen,
Hilden, Germany) were used for these probe-based
real-time PCR assays according to the manufacturer’s
instructions in a 10 lL reaction volume. A common
reverse primer was designed to target the 50-prime tail
of all mutation-specific ExBP-RT products. The
expression levels of total BRAF genes (including
V600E mutant and its wild-type segments) were also
determined in each sample for normalization using
QuantiTect SYBR Green PCR Kits (Qiagen) accord-
ing to the manufacturer’s instructions in a 10 lL vol-
ume. The sequences and concentration of qPCR
primers and probes are provided in Table 2. The same
thermocycling conditions were used for both probe-
based and SYBR Green-based real-time quantitative
PCR (qPCR): 95 °C for 15 min, 45 cycles at 94 °C for
10 s, at 60 °C for 45 s. Following SYBR Green-based
qPCR, the specificity of the amplification products was
verified by melting curve analysis. All qPCR assays
were run on a LightCycler 480 II Real-Time PCR
Instrument (Roche Applied Science, Mannheim, Ger-
many) with a 384-well white-plate (Roche Applied
Science). All mutation, wild-type, and H2O controls of
each experiment were checked to verify the results in
both ExBP-RT and qPCR assays. Threshold cycle (Ct)
values of qPCR were calculated automatically using
the absolute quantification analysis with the fit points
method, which is built in the LightCycler 480 II sys-
tem. The method allows to setting the noise band and
the threshold line in order to discard uninformative
background noise.
2.3. Real-time quantitative PCR
For FFPE samples, 500 ng of total RNA was reverse-
transcribed with 100 U Revert Aid Premium Reverse
Transcriptase (Thermo Fisher Scientific, Waltham, MA,
USA) using 4 pmol of gene-specific antisense primers
for SPINK1 and RPL13A (see below for sequences),
0.5 mM dNTP mix, and 20 U Ribolock RNAse inhibi-
tor (all from Thermo Fisher Scientific). Possible con-
tamination of RNA in FFPE-extracted samples with
SPINK1 or RPL13A DNA was excluded by subjecting
each sample to RT reaction without Revert Aid
Table 1. Patient characteristics.
All patients N = 571 n %
Age < 65 231 40
≥ 65 340 60
Gender Female 264 46
Male 307 54
Type Adeno 513 90
Mucinous 58 10
Location Colon 381 67
Rectum 190 33
Side Dex 201 35
Sin 369 65
Dukes A 74 13
B 211 37
C 166 29
D 120 21
Grade 1 28 5
2 392 69
3 109 19
4 21 4
Age (min–max), years 68.1 (29.3–97.2)
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Premium Reverse Transcriptase. Real-time qPCR was
performed with a LightCycler 480 II instrument using a
384-well thermal block (Roche Applied Science) with
SensiFAST SYBR No-ROX Kit (Bioline, London,
UK). SPINK1, PRSS1, and PRSS2 qPCR from cell
lines was performed using the conditions described pre-
viously (R€as€anen et al., 2016b). The following primers,
purchased from TAG Copenhagen (Copenhagen, Den-
mark) and verified earlier (R€as€anen et al., 2016b), were
used: SPINK1 forward 50-TGT CTG TGG GAC TGA
TGG AA, SPINK1 reverse 50-GCC CAG ATT TTT
GAA TGA GG, PRSS1 forward 50-CCA CCC CCA
ATA CGA CAG GAA G, PRSS1 reverse 50-GCG
CCA GAG CTC GCA GT, PRSS2 forward 50-CCA
AAT ACA ACA GCC GG, PRSS2 reverse 50-AGT
CGG CAC CAG AAC TCA GA, RPL13A forward 50-
AGA TGG CGG AGG TGC AG and RPL13A reverse
50-GGC CCA GCA GTA CCT GTT TA.
Following SYBR Green-based qPCR, the specificity
of the amplification products was verified by melting
curve analysis and a control sample was included in
every run to confirm interassay reproducibility. All reac-
tions were run in duplicate, and for all samples, RT-con-
trols were run to exclude possible DNA contamination.
Relative expression of target gene mRNA referenced to
RPL13A housekeeping gene was calculated using the
ΔΔCt method (Livak and Schmittgen, 2001).
Human transcription factors (non-HOX) TaqMan
Array (Thermo Fisher Scientific) that contains 92
assays for non-HOX transcription factor-associated
genes and four assays for endogenous control genes
were performed according to the manufacturer’s
protocol.
2.4. Immunohistochemistry
SPINK1 immunohistochemistry (IHC) was performed
as described recently (R€as€anen et al., 2016b). Briefly,
FFPE sections were deparaffinized with xylene and
rehydrated in ethanol series. Mouse monoclonal anti-
SPINK1 (2 lgmL1, in-house clone 6E8) (Osman
et al., 1993) was incubated overnight at 4 °C. Isotype
control antibody was mouse IgG #I-2000 (Vector Lab-
oratories, Burlingame, CA, USA). Mach 4 Universal
AP-Polymer kit (Biocare Medical, Concord, CA,
USA) was used for detection, and the visualization sig-
nal was developed with Vector Red Alkaline Phos-
phatase Substrate kit (Vector Laboratories).
2.5. Cell culture
BRAF V600E CRC cell lines Colo205 and HT-29
(American Type Culture Collection, Manassas, VA,
USA), and BRAF wild-type cell lines Caco-2, and
SW-480 (Sigma-Aldrich, St. Louis, MO, USA), were
cultured and authenticated as previously described
(R€as€anen et al., 2016b). Melanoma cell lines
SK-MEL-2 (BRAF wild-type) and SK-MEL-5 (BRAF
V600E) were purchased from American Type Culture
Collection and grown in EMEM. All cell lines were
cultured at +37 °C in 5% CO2 atmosphere and supple-
mented with 5% fetal bovine serum (Biowest, Nuaille,
France), 0.3 mgmL1 glutamine, 100 lgmL1 strep-
tomycin, and 100 UmL1 penicillin (all from Lonza,
Basel, Switzerland). Cells were used until passage num-
ber 20 and routinely tested for mycoplasma.
2.6. Inhibitors
The following inhibitors were purchased from Selleck
Chemicals (Munich, Germany) and dissolved in DMSO
according to the manufacturer’s instructions: gefitinib
(EGFR), GW5074 (CRAF), LY294002 (AKT), PD98059
(MEK1), salisarib (RAS), SCH772984 (ERK1/2), trame-
tinib (MEK1/2), vemurafenib (BRAF), and zoledronic
acid (RAS and RHO).
2.7. Immunofluorometric assay
Time-resolved immunofluorometric assays (IFMA) devel-
oped in-house for SPINK1, trypsinogen-1, and trypsino-
gen-2 (Itkonen et al., 1990; Janeiro et al., 2012; Koivunen
Table 2. Primer and probe sequences for qPCR step of different ExBP-RT assays (locked nucleic acid (LNA) = [+A], [+G], [+C], [+T];
inosine = i; 6-carboxyfluorescein: FAM; black hole quenchers: BHQ).
Primers and probes Sequences (50–30) Concentrations, lM
Mutant BRAF V600E assays
BRAF forward primer 50-AGACCTCACAGTAAAAATAGGTGA-30 0.5
Common reverse primer 50-CGATCAGACGACGAC-30 0.5
BRAF-Probe FAM-TTC[+T]CT[+G]TA[+G]CT[+A]GACCAA-BHQ1 0.1
Total BRAF assays
Total BRAF forward primer 50-CATGAAGACCTCACAGTAAA-30 1.5
Total BRAF reverse primer 50-GATTTCACTGTAGCTAGACC-30 1.5
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et al., 1990; Paju et al., 2001) were performed as described
previously (R€as€anen et al., 2016b). The concentrations of
secreted proteins were measured from 24-, 48-, and 72-h
conditioned media with or without various inhibitor
treatments. The detection ranges for the IFMAs are the
following: SPINK1 0.5–90 ngmL1, trypsinogen 1 1.6–
400 ngmL1, and trypsinogen 2 2–500 ngmL1.
2.8. Western blotting
Samples for western blot analysis were harvested as
described (R€as€anen et al., 2008). Samples were run on
4–12% gradient gels (Life Technologies, Carlsbad,
CA, USA). Using Trans-Blot Turbo system, proteins
were transferred to nitrocellulose membrane (both
from Bio-Rad, Hercules, CA, USA) and blocked with
5% (w/v) nonfat powdered milk in TBS (20 mM Tris/
HCl pH 7.5, 150 mM NaCl, and 0.1% Tween-20).
Immunoreactive proteins were visualized with appro-
priate primary and secondary antibodies using ECL
detection (Bio-Rad).
The following primary antibodies were used accord-
ing to the manufacturers’ recommended dilutions: rab-
bit monoclonal anti-phospho-p44/42 MAPK (ERK1/2,
Thr202/Tyr204), rabbit polyclonal anti-p44/42 MAPK
(ERK1/2), rabbit monoclonal anti-phospho-MEK1/2
(Ser217/221), mouse monoclonal anti-MEK1/2
(L38C12), rabbit polyclonal anti-phospho-STAT3
(Y705), mouse monoclonal anti-STAT3 (124H6), and
rabbit monoclonal anti-ATF4 (D4B8) (all from Cell
Signaling Technology, Danvers, MA, USA). Rabbit
polyclonal anti-GAPDH was from Sigma-Aldrich. The
secondary antibodies used in western blotting were
affinity-purified horseradish peroxidase-coupled anti-
rabbit IgG H+L and anti-mouse IgG H+L (both from
Jackson ImmunoResearch, Suffolk, UK).
2.9. Statistical analysis
Results are given as the number of patients and per-
centage or mean and SD or median and range or
interquartile range (IQR). The Fisher’s exact test and
the linear-by-linear association test were used to assess
associations between clinicopathological variables and
mutation status or mRNA expression. The relative
SPINK1 mRNA expression was dichotomized at
87.5% percentile. Differences in continuous variables
between different groups were tested with the unpaired
t-test or with the Mann–Whitney test or in the case of
ordinal grouping variable with the Jonckheere–Terp-
stra test. Survival analysis was performed with the
Kaplan–Meier method, and the log-rank test was used
to compare the groups. The Cox regression
proportional hazard model was used for uni- and mul-
tivariate survival analyses. Multivariate analysis was
adjusted for age, gender, stage, and location. Interac-
tion terms were considered. The Cox model assump-
tion of constant hazard ratios over time was tested. A
time-dependent covariate was included separately for
each testable variable at a time. A time-dependent cor-
rection factor was included in the models, if the hazard
ratio was not constant over time. The Spearman’s rho
correlation coefficient was calculated to assess the cor-
relation between continuous and ordinal variables. All
in vitro experiments were conducted in duplicate and
repeated three times. P-values of less than 0.05 were
considered to be statistically significant, and two-tailed
tests were used. Statistical analyses were carried out
with SPSS (version 24; IBM, New York, NY, USA) and
GraphPad software (La Jolla, CA, USA).
3. Results
3.1. BRAF V600E mutation detection by ExBP-RT
assay
BRAF V600E mutation is known to be a strong mar-
ker of poor prognosis in metastatic CRC. The preva-
lence of this mutation is around 10% (Dienstmann
and Tabernero, 2016). We detected expressed BRAF
V600E mutations in 8% of the samples in our cohort,
and the presence of BRAF V600E correlated signifi-
cantly with poor prognosis (the log-rank test,
P < 0.001). Patients with no detected expression of
V600E mutations had a mean survival time of 16.1
(95% CI, 15.0–17.2) years compared to 11.1 (8.0–14.2)
years for patients with expressed mutations (Fig. 1). In
univariate Cox analysis, the hazard ratio for expressed
BRAF V600E mutations was 2.1 (95% CI, 1.5–3.0,
P < 0.001), and in multivariate model after adjusting
for age, gender, stage, and location, it was 2.8 (95%
CI, 1.8–4.4, P = < 0.001) (Table 3).
3.2. Low expression of tumor SPINK1 mRNA
associates with poor prognosis
First, we correlated the SPINK1 mRNA qPCR data
with the previously published (Koskensalo et al., 2012)
immunohistochemistry result of this cohort. The rela-
tive expression level of SPINK1 measured by qPCR
significantly correlated with the previous IHC results
(Spearman’s rho 0.366, P < 0.001, n = 242). Represen-
tative images of SPINK1 IHC and corresponding rela-
tive SPINK1 mRNA levels are shown in Fig. 2A.
Further, in line with the reported result of the IHC
staining where low SPINK1 immunoreactivity was an
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independent prognostic factor for adverse outcome
(Koskensalo et al., 2012), low SPINK1 mRNA expres-
sion was associated with poor prognosis (Fig. 2B, the
log-rank test, P = 0.033). This was more prominent in
patients having disease on the left side (Fig. 2C, the
log-rank test P = 0.004). Patients with high SPINK1
mRNA level (> 2.4 on a relative scale) and left-side
disease had a mean survival time of 17.4 (95% CI,
14.9–19.8) years compared to 14.5 (95% CI, 12.9–16.1)
years for patients with lower SPINK1 mRNA level
(≤ 2.4). In univariate Cox analysis, the hazard ratio
for SPINK1 mRNA level was 0.51 (95% CI, 0.29–
0.91, P = 0.023, relative mRNA expression = > 2.4 vs
< 0.5) and 0.43 (95% CI, 0.22–0.84, P = 0.014) in mul-
tivariate model adjusted for age, gender, stage, and
location (Table 3).
3.3. Correlation of expressed BRAF V600E
mutations with SPINK1 expression
As the independent analyses of expressed BRAF
V600E mutations and low SPINK1 expression were
indicative of poor prognosis, we analyzed the correla-
tion between these two biomarkers. Expressed BRAF
V600E mutation correlated negatively with both
SPINK1 mRNA expression level (Spearman’s rho
0.19, P < 0.001) and the previously published
(Koskensalo et al., 2012) IHC results (Spearman’s
rho 0.21, P < 0.001). The relative SPINK1 mRNA
expression was lower in samples with the expression
of mutated BRAF V600E (median 0.4, IQR 0.1–0.6)
than in samples with BRAF wild-type expression only
(median 0.8, IQR 0.3–1.5, P = < 0.0001, Mann–Whit-
ney test). The hazard ratio of high SPINK1 mRNA
level (> 2.4) in patients with expression of wild-type
BRAF to patients with expressed BRAF V600E
mutations was 0.09 (95% CI, 0.03–0.27) after adjust-
ing for age, gender, stage, and location. All patients,
except one, with expressed BRAF V600E mutations
had low SPINK1 mRNA levels (≤ 2.4 relative
expression).
3.4. Effect of MAPK inhibitors on SPINK1
secretion
Next, we analyzed the levels of secreted SPINK1 and
its putative serine protease targets trypsin-1 and tryp-
sin-2 in a panel of CRC and melanoma cell lines har-
boring either wild-type or V600E BRAF. Table 4
shows the basal levels of SPINK1, trypsin-1, and tryp-
sin-2 at 72-h time point in a panel of cell lines and
their respective BRAF status. Notably, neither of the
melanoma cell lines secreted SPINK1 or trypsins.
In order to study the effects of various MAPK path-
way inhibitors on the SPINK1 levels, CRC cell lines
were treated with the following compounds: gefitinib,
GW5074, LY294002, PD98059, salisarib, SCH772984,
trametinib, vemurafenib, and zoledronic acid. In
BRAF V600E CRC cells lines Colo205 and HT-29,
inhibitors affecting the MAPK pathway at or below
BRAF resulted in over twofold dose-dependent
increase in SPINK1 secretion measured at 72-h time
point (Fig. 3A,B). This effect was seen with the BRAF
inhibitor vemurafenib and subsequent MAPK pathway
inhibitors trametinib (MEK1/2 inhibitor) and
SCH772984 (ERK1/2 inhibitor), but interestingly not
with the CRAF inhibitor GW5074 or with PD98059
that is a non-ATP competing MEK antagonist specifi-
cally inhibiting MEK1-mediated activation of the
MAPK pathway. Further, inhibitors upstream of
RAF, such as the RAS inhibitor salisarib, RAS/RHO
inhibitor zoledronic acid, or EGFR inhibitor gefitinib
did not induce SPINK1 secretion in BRAF V600E
CRC cells. These effects were not seen in the BRAF
wild-type CRC cell line Caco-2 (Fig. 3C). Akt inhibi-
tor LY294002 did not affect SPINK1 levels in any of
the tested cell lines.
3.5. MAPK inhibitors induce SPINK1 and
concomitantly downregulate trypsin-1 and -2 in
BRAF V600E cells
To further elucidate the effects of the MAPK pathway
inhibitors on CRC cells, using the minimum dose that
induced SPINK1 secretion in Colo205 in HT-29 cells
(60 nM), we measured the levels of SPINK1 in a time-
dependent manner. At 48- and 72-h time points in
Fig. 1. Survival curves for BRAF wild-type- and V600E-expressing
colorectal cancer patients.
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Table 3. Statistical analyses of expressed BRAF V600E mutations and SPINK1 expression.
HR
95% CI
PLower Upper
Univariate
Age 65 year, age = > 65 vs < 65 1.45 1.11 1.90 0.006
Gender, male vs female 1.03 0.80 1.34 0.807
Dukes
A 1.00
B 2.09 0.98 4.45 0.056
C 6.52 3.15 13.49 0.000
D 27.92 13.48 57.84 0.000
Grade
1 1.00
2 1.96 0.87 4.42 0.106
3 2.88 1.24 6.71 0.014
4 3.09 1.12 8.50 0.029
Location, rectum vs colon 1.25 0.96 1.64 0.095
Side, sin vs dex 1.25 0.95 1.66 0.116
Type, mucinous vs adeno 0.93 0.61 1.42 0.744
BRAF V600E mutation, yes vs no 2.12 1.48 3.03 0.000
SPINK1 mRNA, continuous 0.93 0.85 1.01 0.098
SPINK1 mRNA dichotomous, > 2.4 vs ≤ 2.4 0.556 0.321 0.961 0.036
SPINK1 mRNA
< 0.5 1
0.5–2.4 0.87 0.63 1.20 0.403
≥ 2.4 0.51 0.29 0.91 0.023
BRAF V600E and SPINK1 mRNA
BRAF V600E mutation 1.00
SPINK1 ≤ 2.4, no mutation in BRAF 0.40 0.26 0.62 0.000
SPINK1 > 2.4, no mutation in BRAF 0.23 0.12 0.45 0.000
Multivariate BRAF
Age 65 year, age = > 65 vs < 65 2.01 1.52 2.66 0.000
Gender, male vs female 1.14 0.87 1.48 0.344
Dukes
A 1
B 2.17 1.01 4.66 0.047
C 7.08 3.39 14.76 0.000
D 32.16 15.36 67.33 0.000
Location, rectum vs colon 1.47 1.12 1.93 0.006
BRAF V600E mutation, yes vs no 2.84 1.84 4.40 0.000
BRAF V600E time dependent, after 2 years of survival 0.16 0.05 0.54 0.003
Multivariate SPINK1
Age 65 year, age = > 65 vs < 65 2.20 1.58 3.07 0.000
Gender, male vs female 1.12 0.81 1.54 0.489
Dukes
A 1
B 2.68 1.02 7.02 0.045
C 8.71 3.44 22.06 0.000
D 40.93 16.03 104.52 0.000
Location, rectum vs colon 1.66 1.19 2.32 0.003
SPINK1 mRNA
< 0.5 1
0.5–2.4 0.72 0.50 1.02 0.061
≥ 2.4 0.43 0.22 0.84 0.014
SPINK1 mRNA time dependent, after five years of survival 2.48 1.13 5.41 0.023
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Table 3. (Continued).
HR
95% CI
PLower Upper
Multivariate SPINK1 and BRAF
Age 65 year, age = > 65 vs < 65 2.12 1.51 2.96 0.000
Gender, male vs female 1.13 0.82 1.55 0.465
Dukes
A 1
B 2.77 1.06 7.28 0.038
C 8.79 3.47 22.26 0.000
D 43.59 17.02 111.65 0.000
Location, rectum vs colon 1.75 1.25 2.45 0.001
BRAF V600E and SPINK1 mRNA
BRAF V600E mutation 1
SPINK1 ≤ 2.4, no mutation in BRAF 0.29 0.17 0.47 0.000
SPINK1 > 2.4, no mutation in BRAF 0.09 0.03 0.27 0.000
BRAF V600E and SPINK1 mRNA, after 2 years of survival 3.49 1.43 8.54 0.006
a
A
b
B
c
C
Fig. 2. (A) Representative IHC images of SPINK1 (a) negative, (b) positive (< 2.4), and (c) positive (> 2.4) immunoexpression. Images taken
at 109 magnification. The value below is the relative SPINK1 mRNA expression in the same sample calculated using the ΔΔCt method. (B)
Survival curves for SPINK1 mRNA (< 2.4) and (> 2.4) colorectal cancer patients. (C) Survival curves for SPINK1 mRNA (< 2.4) and (> 2.4)
colorectal cancer patients having disease on the left side.
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both cell lines, vemurafenib, trametinib, and
SCH772984 resulted in a statistically significant
increase in SPINK1 secretion (P < 0.05) compared to
control, as measured by IFMA (Fig. 4A,B, top pan-
els). Corroborating the immunoassay results, SPINK1
mRNA levels were increased at the 72-h time point in
response to vemurafenib, trametinib, and SCH772984
in both cell lines (Fig. S1A).
Furthermore, as SPINK1 is a putative trypsin inhi-
bitor, we investigated whether the MAPK inhibitors
affected endogenous trypsin levels in the CRC cell
lines. In the BRAF V600E Colo205 cells, vemurafenib,
trametinib, and SCH772984 led to a statistically signif-
icant (P < 0.05) decrease in trypsin-1 (Fig. 4A, mid-
panel) and trypsin-2 (Fig. 4A, bottom panel) levels at
72-h time point, suggesting inverse regulation between
SPINK1 and its target proteases. In the other BRAF
V600E cell line HT-29 (Fig. 4B), vemurafenib and
SCH772984 led to statistically significant (P < 0.05)
decrease in trypsin-1 and -2 levels, whereas in trame-
tinib-treated cells trypsin-1 and -2 levels did not
decrease. These data were confirmed by qPCR analy-
ses of the mRNA levels of PRSS1 (trypsin-1) and
PRSS2 (trypsin-2) (Fig. S1B, C).
In the BRAF wild-type cell line Caco-2, level of
SPINK1 was slightly increased in response to trametinib
at 48-h time point, but not in response to vemurafenib
and SCH772984, as analyzed by IFMA (Fig. 4C). Tryp-
sin-1 levels were not affected by inhibitors (Fig. 4C,
right panel) and trypsin-2 was not detected in the Caco-
2 cell conditioned media by IFMA. The results were
confirmed by qPCR analyses of the mRNA levels of
SPINK1, PRSS1 (trypsin-1), and PRSS2 (trypsin-2),
indicating a correlation between mRNA expression and
secretion of these proteins (Fig. S1).
3.6. Trametinib diminishes ERK1/2 and MEK1/2
phosphorylation and downregulates ATF-4
To elucidate the signaling events that led to increased
SPINK1 expression in response to MAPK inhibitors,
we studied the phosphorylation status of MEK1/2 and
ERK1/2 at 24-h time point (Fig. 5). In both Colo205
and HT-29 cells, trametinib diminished completely the
phosphorylated forms of ERK1/2 (Thr202/Tyr204)
and MEK1/2 (Ser217/221). However, vemurafenib and
SCH772984 reduced phosphorylation of ERK1/2 and
MEK1/2 to a much lesser extent compared to trame-
tinib. These results were in line with the observed
increase in SPINK1 levels in these cells. Further,
PD98059, which did not affect SPINK1 expression
(Fig. 4), did not affect the phosphorylation status of
ERK1/2 or MEK1/2 in either CRC cell line.
Next, we performed a TaqMan non-HOX transcrip-
tion factor array in order to identify which transcrip-
tion factor is responsible for the increased SPINK1
expression. As trametinib caused the biggest increase
in SPINK1 level in both cell lines, we used it at 60 nM
concentration and harvested RNA at 24-h time point.
Interestingly, none of the transcription factors included
in the array were significantly induced in the trame-
tinib-treated Colo205 and HT-29 cells (Fig. 6A). The
only transcription factor with a change in its mRNA
level in the trametinib-treated sample compared to the
DMSO control was activating transcription factor 4
(ATF-4), a transcription factor linked to integrated
stress response (ISR) (Pakos-Zebrucka et al., 2016).
The decrease in ATF-4 caused by trametinib was
further confirmed by western blotting (Fig. 6B).
As we have previously shown that interleukin-6
induces SPINK1 expression in Colo205 and HT-29 cells
via STAT3 phosphorylation (R€as€anen et al., 2016b), we
investigated whether this was also the case with the
MAPK inhibitors. Phosphorylation of STAT3 was not
induced in response to the inhibitors (data not shown)
and the total STAT3 levels remained constant (Fig. S2).
4. Discussion
CRC patients with the BRAF V600E mutation present
a clinical challenge, as no effective treatments have
been found for this subpopulation. In keeping with
previously published results (Barras, 2015), patients
with this mutation have a decreased survival rate in
Table 4. Basal levels of secreted SPINK1, trypsin-1 and -2 at 72-h time point.
Cancer type Cell line BRAF status SPINK1, ngmL1 Trypsin-1, ngmL1 Trypsin-2, ngmL1
CRC Colo205 V600E 1.6 ( 0.06) 12.2 ( 0.8) 56 ( 6.2)
CRC HT-29 V600E 11.4 ( 2.4) 2.5 ( 0.3) 3.9 ( 0.5)
CRC Caco-2 WT 35.3 ( 4.3) 1.3 ( 0.3) ND
CRC SW480 WT ND ND ND
Melanoma SK-MEL-2 WT ND ND ND
Melanoma SK-MEL-5 V600E ND ND ND
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our cohort. Several publications have shown that
SPINK1 plays a role in the tumorigenesis of CRC, in
particular at the later stages (R€as€anen et al., 2016a).
In this study, we demonstrate that SPINK1 protein
and mRNA levels correlate and that low SPINK1
expression in tumor tissue is indicative of poor prog-
nosis, in line with our previously published results
(Koskensalo et al., 2012) and with a recent publication
(Chen et al., 2016) in which high SPINK1 tumor
expression correlated with a good prognosis in patients
with CRC receiving cetuximab therapy. Further, here
we show for the first time that expression of BRAF
V600E mutation correlates with low SPINK1 expres-
sion level. The ExBP-RT method used for the BRAF
V600E analyses detects mRNA of expressed mutations
in tumor tissue, rather than the presence of mutated
Fig. 3. MAPK pathway inhibitors increase SPINK1 levels in BRAF V600E colorectal cancer. Secreted SPINK1 protein levels were analyzed
by IFMA in Colo205 (A), HT-29 (B), and (C) Caco-2 cells at 72-h time point. Vemurafenib, trametinib, and SCH772984 increased SPINK1
secretion in Colo205 and HT-29 cells over twofold (dashed line), whereas no twofold increase was seen in the Caco-2 cells compared to
control and DMSO-treated cells.
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DNA. This allowed us to use the same patient samples
to analyze the expression of both SPINK1 and BRAF
V600E mRNA.
These clinical findings of BRAF V600E and SPINK1
expression in our CRC patient cohort led us to hypothe-
size that MAPK inhibitors might affect SPINK1 levels.
In order to test this, we used a panel of CRC cell lines
harboring the V600E-mutant BRAF and compared the
effects to a BRAF wild-type CRC cell line. Vemurafenib
treatment is not beneficial in BRAF-mutant CRC
patients and combination therapies with MAPK inhibi-
tors with EGFR inhibitors are under clinical investiga-
tions. A phase I study by Corcoran et al. (2015)
suggested that dual MAPK pathway blockade with the
BRAF inhibitor dabrafenib and the MEK inhibitor
trametinib can lead to a meaningful clinical benefit in a
subset of patients with BRAF V600E metastatic CRC.
Based on our results, trametinib treatment, which
inhibits both MEK1 and MEK2, might be an effec-
tive therapy in BRAF V600E-positive/SPINK1-low sub-
population of patients with CRC, as it led to increased
SPINK1 secretion in BRAF V600E-positive CRC cells.
Furthermore, it was the only MAPK inhibitor that was
able to diminish phosphorylation of MEK and ERK in
the BRAF V600E CRC cell lines Colo205 and HT-29.
Our data also support both preclinical and clinical find-
ings that vemurafenib is not effective in BRAF-mutant
CRC, as it was not capable to completely suppress
MAPK signaling. As PD98059, a MEK1 inhibitor, was
not able to affect SPINK1 secretion or MEK and ERK
phosphorylation, our data implicate MEK2 as a critical
protein in the MAPK pathway in colorectal adenocarci-
noma.
Bidirectional kinase–protease interactions are known
to have a role in cancer and clinical implications of
such kinase–protease crosstalk have started to emerge
(Lopez-Otin and Hunter, 2010). In our study, parallel
to SPINK1 increase, we observed a decrease in the
expression and secretion of trypsin-1 and -2 in
response to vemurafenib, trametinib, and SCH772984.
Studies have suggested that robust MAPK pathway
suppression is required for response in BRAF V600E
cancers and acquired resistance to BRAF inhibitor
combinations involve reactivation of the MAPK path-
way (Ahronian et al., 2015). Recently, Miller et al.
(2016) showed that MEK inhibitors lead to a reduced
proteolytic shedding of cell surface receptor tyrosine
kinases by inhibiting the catalytic activity of a disinte-
grin and metalloproteinases (ADAM), thus leading to
increased mitogenic signaling and kinase inhibitor
resistance. Further, disrupting the protease inhibition
by neutralizing a putative ADAM10 inhibitor tissue
inhibitor of metalloproteinases 1 (TIMP1), MAPK
inhibitor efficacy was improved (Miller et al., 2016).
These findings, along with ours, highlight the extensive
crosstalk between kinases, proteases, and cognate
Fig. 5. Trametinib diminishes ERK and MEK phosphorylation in BRAF V600E CRC cells. ERK1/2 (Thr202/Tyr204) and MEK1/2 (Ser217/221)
residues are dephosphorylated by trametinib (60 nM) as shown by a western blot of whole-cell lysates of Colo205 and HT-29 cell lines at 24-
h time point. Vemurafenib and SCH772984 reduce ERK1/2 (Thr202/Tyr204) and MEK1/2 (Ser217/221) phosphorylation to a lesser extent in
Colo205 and HT-29 cells. Vemurafenib (Vem.), trametinib (Tram.), SCH772984 (SCH), or PD98059 (PD). Total ERK1/2 and MEK1/2 antibodies
were used as controls.
Fig. 4. Time-dependent increase in SPINK1 levels in response to vemurafenib, trametinib, and SCH772984 in Colo205 and HT-29 cells. (A) In
Colo205 cells, vemurafenib, trametinib, and SCH772984 significantly increased SPINK1 secretion at 48- and 72-h time points with a
concomitant decrease in trypsin-1 and -2 secretion at 72-h time point as measured by respective IFMAs. (B) In HT-29 cells, vemurafenib,
trametinib, and SCH772984 significantly increased SPINK1 secretion at 48- and 72-h time points. Vemurafenib and SCH772984, but no
trametinib, reduced trypsin-1 and -2 levels in HT-29 cells at 72-h time point. (C) Vemurafenib, trametinib, and SCH772984 did not increase
SPINK1 secretion or decrease trypsin-1 secretion in Caco-2 cells compared to control or DMSO-treated cells. Significantly different (*P < 0.05)
as compared to control by two-tailed t-test. Trypsin-2 was not detected in HT-29 cells at 24-h time point and in Caco-2 cells at any time point.
235Molecular Oncology 12 (2018) 224–238 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
K. R€as€anen et al. SPINK1 secretion in BRAF V600E colon cancer
protease inhibitors in response to molecularly targeted
therapies and warrant further studies.
Here, we describe a novel mechanism of ATF-4 tran-
scription repression by molecularly targeted therapy, as
trametinib was able to downregulate ATF-4 transcrip-
tion leading to reduced ATF-4 protein level in Colo205
and HT-29 cells. ATF-4 is a well-characterized effector
of ISR. It has several dimerization partners that influ-
ence its gene transcription, thus guiding cellular out-
comes (Pakos-Zebrucka et al., 2016). In most cases,
cellular stress induces upregulation of ATF-4 transcrip-
tion. For example, in BRAF inhibitor-sensitive mela-
noma cell lines, the preclinical version of vemurafenib,
PLX4720, led to a rapid induction of ATF-4 (Ma et al.,
2014). However, there is evidence of transcriptional
repression of ATF-4 by some cellular stressors, such as
C/EBPb during UV irradiation and in nonalcoholic
fatty liver and nonalcoholic steatohepatatis (Pakos-Zeb-
rucka et al., 2016). Of note, the mechanism by which
these MAPK inhibitors activate SPINK1 transcription
remains to be revealed, as on the transcription factor
array we did not observe any significant increases in
response to the trametinib treatment.
5. Conclusions
In conclusion, this study demonstrates for the first
time an inverse relationship between expressed BRAF
Fig. 6. Trametinib downregulates ATF-4 mRNA and protein levels. (A) Colo205 and HT-29 cells were treated with 60 nM trametinib for 24 h
after which RNA was extracted and TaqMan non-HOX transcription factor array was performed. ATF-4 mRNA was decreased by twofold in
response to trametinib when compared to DMSO control. (B) Western blot of whole-cell lysates of Colo205 and HT-29 cells harvested after
24-h treatment with either 60 nM vemurafenib (Vem.), trametinib (Tram.), SCH772984 (SCH), or PD98059 (PD) showing downregulation of
ATF-4 protein level in response to vemurafenib. GAPDH was used as a loading control.
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V600E mutations and SPINK1 expression. Further,
we show that in addition to downregulating phospho-
rylation of ERK and MEK, trametinib treatment leads
also to downregulation of ATF-4 and trypsin-1 and -2
with a concomitant increase in SPINK1 secretion.
Both ATF-4 and trypsins have been shown to confer
survival advantage of cancer cells and thereby to regu-
late tumor progression. Thus, finding an effective way
to inhibit the expression of these proteins while sus-
taining SPINK1 levels might have a clinical benefit in
BRAF V600E-positive colorectal adenocarcinoma.
Although further studies are warranted, SPINK1
expression seems to be a useful biomarker in CRC and
its expression might guide patient stratification and
treatment response to molecularly targeted therapies.
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